5/15
02:09 pm
hrow
Harrow, Inc. (NASDAQ: HROW) had its price target raised by analysts at Craig Hallum from $24.00 to $26.00. They now have a "buy" rating on the stock.
Low
Report
Harrow, Inc. (NASDAQ: HROW) had its price target raised by analysts at Craig Hallum from $24.00 to $26.00. They now have a "buy" rating on the stock.
5/15
10:29 am
hrow
Harrow, Inc. (NASDAQ: HROW) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $29.00 price target on the stock, up previously from $26.00.
Medium
Report
Harrow, Inc. (NASDAQ: HROW) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $29.00 price target on the stock, up previously from $26.00.
5/15
07:00 am
hrow
Harrow to Present at Two Investor Conferences in May
Low
Report
Harrow to Present at Two Investor Conferences in May
5/13
04:01 pm
hrow
Harrow Announces First Quarter 2024 Financial Results
High
Report
Harrow Announces First Quarter 2024 Financial Results
5/13
07:00 am
hrow
Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
Low
Report
Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
4/25
07:00 am
hrow
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
Low
Report
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
4/11
08:00 am
hrow
Harrow Health, Inc. (NASDAQ: HROW) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $24.00 price target on the stock.
Neutral
Report
Harrow Health, Inc. (NASDAQ: HROW) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $24.00 price target on the stock.
4/2
08:16 am
hrow
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
Low
Report
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
3/25
08:07 am
hrow
Harrow Health, Inc. (NASDAQ: HROW) had its price target lowered by analysts at B. Riley from $30.00 to $26.00. They now have a "buy" rating on the stock.
Medium
Report
Harrow Health, Inc. (NASDAQ: HROW) had its price target lowered by analysts at B. Riley from $30.00 to $26.00. They now have a "buy" rating on the stock.
3/21
10:01 am
hrow
Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/19
05:45 pm
hrow
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
High
Report
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
3/5
07:00 am
hrow
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
Low
Report
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024